P30 AI045008-05/AI/NIAID NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2008	1
2010	2
2025	0

Page 1

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM. Wilkin TJ, et al. J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6. doi: 10.1097/qai.0b013e3181e2cba0. J Acquir Immune Defic Syndr. 2010. PMID: 20672447 Free PMC article. Clinical Trial.

A spatially varying two-sample recombinant coalescent, with applications to HIV escape response.

Braunstein A, Jensen ST, Wei Z, McAuliffe JD. Braunstein A, et al. Adv Neural Inf Process Syst. 2008;21:662. Adv Neural Inf Process Syst. 2008. PMID: 20531976 Free PMC article.

Is antiretroviral therapy adherence substantially worse on weekends than weekdays?

Bachhuber M, Bilker WB, Wang H, Chapman J, Gross R. Bachhuber M, et al. J Acquir Immune Defic Syndr. 2010 May 1;54(1):109-10. doi: 10.1097/QAI.0b013e3181cbd34b. J Acquir Immune Defic Syndr. 2010. PMID: 20418726 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year